EUVIMEDSkopri EUVIMED
Crossref

A Novel Slowly Self‐Emulsifying Drug Delivery System: Prolonged Systemic Exposure of Tacrolimus With Reduced Risks of Systemic Side Effects

Kohei Yamada iD, Keiya Sonobe, Akihisa Miura, Toshinobu Suzuki, Hiroyuki Uchida, Masataka Katsuma, Hideyuki Sato iD, Satomi Onoue iD

Biopharmaceutics & Drug Disposition · 2026-04-10

DOI: 10.1002/bdd.70030 ↗

At a glance

Journal article in Biopharmaceutics & Drug Disposition, published online on 2026-04-10. Written by Kohei Yamada and 7 co-authors. Institution: Laboratory of Biopharmacy, School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka, Japan. 31 references. Funded by: Japan Society for the Promotion of Science.

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

This study aimed to design and characterize a new type of self‐emulsifying drug delivery system (SEDDS), slowly SEDDS (SL‐SEDDS), for long‐lasting systemic exposure of tacrolimus (TAC) with reduced nephrotoxicity. TAC‐loaded SL‐SEDDS (SL‐SEDDS/TAC) was prepared by semi‐solidifying TAC‐loaded SEDDS (SEDDS/TAC) composed of Capryol 90, Cremophor EL, and polyethylene glycol 400 with Geleol. SEDDS samples were evaluated regarding physicochemical and biopharmaceutical properties. Both SEDDS/TAC and SL‐SEDDS/TAC formed fine emulsions in water. The dissolution of SEDDS/TAC reached approximately 100% within the initial 30 min in simulated gastric fluid (SGF), and the SL‐SEDDS/TAC samples exhibited slower dissolution than SEDDS/TAC in a Geleol content‐dependent manner. SL‐SEDDS/TAC with a Geleol content of 17.5 wt% showed 25% dissolution in SGF for 2 h, followed by an additional 31% dissolution in simulated intestinal fluid for 10 h. The sample was selected as a favorable SL‐SEDDS/TAC for further studies because of its slow and continuous dissolution. Oral SEDDS/TAC and the selected SL‐SEDDS/TAC (10 mg‐TAC/kg) offered almost identical bioavailability of 18% and 19%, respectively, in rats. Compared with SEDDS/TAC, SL‐SEDDS/TAC achieved a 32% decrease in the maximum plasma concentration, a risk factor of nephrotoxicity, from 383 to 262 ng/mL with significantly prolonged mean residence time. In a rat model of acute kidney injury, SL‐SEDDS/TAC (10 mg‐TAC/kg/day, 3 days) attenuated the elevation of blood nitrogen urea by 33% compared to SEDDS/TAC, suggesting a reduction in nephrotoxic risks. SL‐SEDDS could be a promising dosage form to control oral absorption of TAC for effective and safe medication.

Subjects

Author keywords

nephrotoxicitypharmacokinetic controlslowly self‐emulsifying drug delivery systemtacrolimus

Authors and institutions

  • Laboratory of Biopharmacy, School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka, Japan.
  • Catalent Japan K.K., Shizuoka, Japan.

ORCID profiles: Kohei Yamada, Hideyuki Sato, Satomi Onoue

Funding

  • Japan Society for the Promotion of Science

Cite

APA

Yamada, K., Sonobe, K., Miura, A., Suzuki, T., Uchida, H., Katsuma, M., Sato, H., & Onoue, S. (2026). A Novel Slowly Self‐Emulsifying Drug Delivery System: Prolonged Systemic Exposure of Tacrolimus With Reduced Risks of Systemic Side Effects. Biopharmaceutics & Drug Disposition. https://doi.org/10.1002/bdd.70030

Vancouver

Yamada K, Sonobe K, Miura A, Suzuki T, Uchida H, Katsuma M, et al. A Novel Slowly Self‐Emulsifying Drug Delivery System: Prolonged Systemic Exposure of Tacrolimus With Reduced Risks of Systemic Side Effects. Biopharmaceutics & Drug Disposition. 2026. doi:10.1002/bdd.70030

BibTeX
@article{Yamada2026,
  author = {Yamada, Kohei and Sonobe, Keiya and Miura, Akihisa and Suzuki, Toshinobu and Uchida, Hiroyuki and Katsuma, Masataka and Sato, Hideyuki and Onoue, Satomi},
  title = {A Novel Slowly Self‐Emulsifying Drug Delivery System: Prolonged Systemic Exposure of Tacrolimus With Reduced Risks of Systemic Side Effects},
  journal = {Biopharmaceutics & Drug Disposition},
  year = {2026},
  doi = {10.1002/bdd.70030}
}
Start for free →